BlackRock Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BlackRock Group’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,992	Closed	-$27K	–	3006
2016 Q3	$27K	Buy	3,992 +171	+4%	+$910	﹤0.01%	2962
2016 Q2	$22K	Sell	3,821 -58	-1%	-$924	﹤0.01%	2991
2016 Q1	$83K	Buy	3,879 +1,661	+75%	+$37.1K	﹤0.01%	2811
2015 Q4	$70K	Sell	2,218 -76	-3%	-$2.68K	﹤0.01%	2768
2015 Q3	$79K	Buy	+2,294	New	+$69.3K	﹤0.01%	2761
2014 Q2	–	Sell	-22,303	Closed	-$425K	–	2876
2014 Q1	$425K	Buy	+22,303	New	+$464K	﹤0.01%	2289

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's MRTX Position: Q4 2016 in Review

BlackRock Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2016, closing a stake of 3,992 shares — an estimated $27K sold.

BlackRock Group first reported a position in MRTX in Q1 2014 and held it in 6 quarters. The position peaked at $425K in Q1 2014. 62 funds tracked by Wall St. Rank hold MRTX as of Q4 2016.

BlackRock Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
BlackRock Group sold 3,992 Mirati Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $27K.
BlackRock Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 6 quarters.
BlackRock Group's Mirati Therapeutics, Inc. Common Stock position peaked at $425K in Q1 2014.
62 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.